[1]
|
Burad, D.K., Kodiatte, T.A., Rajeeb, S.M., et al. (2016) Neuroendocrine Neoplasms of Liver—A 5-Year Retrospective Clinicopathological Study Applying World Health Organization 2010 Classification. World Journal of Gastroenterology, 22, 8956-8966. https://doi.org/10.3748/wjg.v22.i40.8956
|
[2]
|
Parkash, O., Ayub, A., Naeem, B., et al. (2016) Primary Hepatic Carcinoid Tumor with Poor Outcome. Journal of the College of Physicians and Surgeons—Pakistan, 26, 227-229.
|
[3]
|
李晓琼, 张华, 李健丁. 肝脏原发性神经内分泌肿瘤的研究现状[J]. 世界华人消化杂志, 2013, 21(11): 984-989.
|
[4]
|
Dasari, A., Shen, C., Halperin, D., et al. (2017) Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncology, 3, 1335-1342.
https://doi.org/10.1001/jamaoncol.2017.0589
|
[5]
|
Flejou, J.F. (2011) WHO Classification of Digestive Tumors: The Fourth Edition. Annales de Pathologie, 31, S27-S31.
https://doi.org/10.1016/j.annpat.2011.08.001
|
[6]
|
Kulke, M.H., Shah, M.H., Benson 3rd, A.B., et al. (2015) Neuroendocrine Tumors, Version 1. Journal of the National Comprehensive Cancer Network, 13, 78-108. https://doi.org/10.6004/jnccn.2015.0011
|
[7]
|
Park, C.H., Chung, J.W., Jang, S.J., et al. (2012) Clinical Features and Outcomes of Primary Hepatic Neuroendocrine Carcinomas. Journal of Gastroenterology and Hepatology, 27, 1306-1311.
https://doi.org/10.1111/j.1440-1746.2012.07117.x
|
[8]
|
Marotta, V., Zatelli, M.C., Sciammarella, C., et al. (2018) Chromogranin A as Circulating Marker for Diagnosis and Management of Neuroendocrine Neoplasms: More Flaws Than Fame. Endocrine-Related Cancer, 25, R11-R29.
https://doi.org/10.1530/ERC-17-0269
|
[9]
|
Hofland, J., Zandee, W.T. and De Herder, W.W. (2018) Role of Bi-omarker Tests for Diagnosis of Neuroendocrine Tumours. Nature Reviews Endocrinology, 14, 656-669. https://doi.org/10.1038/s41574-018-0082-5
|
[10]
|
Deluzio, M.R., Barbieri, A.L., Israel, G., et al. (2017) Two Cases of Primary Hepatic Neuroendocrine Tumors and a Review of the Current Literature. Annals of Hepatology, 16, 621-629. https://doi.org/10.5604/01.3001.0010.0313
|
[11]
|
Rocca, A., Calise, F., Marino, G., et al. (2014) Primary Giant Hepatic Neuroendocrine Carcinoma: A Case Report. International Journal of Surgery, 12, 218-221. https://doi.org/10.1016/j.ijsu.2014.05.056
|
[12]
|
Herrera Martinez, A.D., Hofland, L., Galvez Moreno, M.A., et al. (2019) Neuroendocrine Neoplasms: Current and Potential Diagnostic, Predictive and Prognostic Markers. Endo-crine-Related Cancer, 26, R157-R179.
https://doi.org/10.1530/ERC-18-0354
|
[13]
|
Li, W., Zhuang, B.W., Wang, Z., et al. (2016) Case Report of Con-trast-Enhanced Ultrasound Features of Primary Hepatic Neuroendocrine Tumor: A CARE-Compliant Article. Medicine, 95, e3450.
https://doi.org/10.1097/MD.0000000000003450
|
[14]
|
Wang, L.X., Liu, K., Lin, G.W., et al. (2015) Primary He-patic Neuroendocrine Tumors: Comparing CT and MRI Features with Pathology. Cancer Imaging, 15, 13. https://doi.org/10.1186/s40644-015-0046-0
|
[15]
|
Yang, K., Cheng, Y.S., Yang, J.J., et al. (2017) Primary Hepatic Neuroendocrine Tumors: Multi-Modal Imaging Features with Pathological Correlations. Cancer Imaging, 17, 20. https://doi.org/10.1186/s40644-017-0120-x
|
[16]
|
郑琴芳, 何志钧, 农兵. 原发性肝脏神经内分泌肿瘤诊断的研究进展芳[J]. 胃肠病学, 2018, 23(8): 506-508.
|
[17]
|
Meng, X.F., Pan, Y.W., Wang, Z.B., et al. (2018) Primary Hepatic Neuroendocrine Tumor Case with a Preoperative Course of 26 Years: A Case Report and Literature Review. World Journal of Gastroenterology, 24, 2640-2646.
https://doi.org/10.3748/wjg.v24.i24.2640
|
[18]
|
Yu, R. and Wachsman, A. (2017) Imaging of Neuroendocrine Tumors: Indications, Interpretations, Limits, and Pitfalls. Endocrinology & Metabolism Clinics of North America, 46, 795-814. https://doi.org/10.1016/j.ecl.2017.04.008
|
[19]
|
Deppen, S.A., Liu, E., Blume, J.D., et al. (2016) Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. Journal of Nuclear Medicine, 57, 708-714.
https://doi.org/10.2967/jnumed.115.163865
|
[20]
|
Barrio, M., Czernin, J., Fanti, S., et al. (2017) The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. Journal of Nuclear Medicine, 58, 756-761. https://doi.org/10.2967/jnumed.116.185587
|
[21]
|
Cives, M. and Strosberg, J.R. (2018) Gastroenteropancreatic Neuroendocrine Tumors. CA: A Cancer Journal for Clinicians, 68, 471-487. https://doi.org/10.3322/caac.21493
|
[22]
|
Ma, G., Li, J., Xu, B., et al. (2018) 18F-FDG PET/CT in Primary Hepatic Neuroendocrine Tumors. Clinical Nuclear Medicine, 43, 192-194. https://doi.org/10.1097/RLU.0000000000001938
|
[23]
|
Panagiotidis, E., Alshammari, A., Michopoulou, S., et al. (2017) Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors. Journal of Nuclear Medicine, 58, 91-96. https://doi.org/10.2967/jnumed.116.178095
|
[24]
|
Song, J.E., Kim, B.S. and Lee, C.H. (2016) Primary Hepatic Neuroendocrine Tumor: A Case Report and Literature Review. World Journal of Clinical Cases, 4, 243-247. https://doi.org/10.12998/wjcc.v4.i8.243
|
[25]
|
Chen, R.W., Qiu, M.J., Chen, Y., et al. (2018) Analysis of the Clinicopathological Features and Prognostic Factors of Primary Hepatic Neuroendocrine Tumors. Oncology Letters, 15, 8604-8610. https://doi.org/10.3892/ol.2018.8413
|
[26]
|
Shi, C., Zhao, Q., Dai, B., et al. (2018) Primary Hepatic Neuroendocrine Neoplasm: Long-Time Surgical Outcome and Prognosis. Medicine, 97, e11764. https://doi.org/10.1097/MD.0000000000011764
|
[27]
|
Maxwell, J.E., Sherman, S.K., Stashek, K.M., et al. (2014) A Practical Method to Determine the Site of Unknown Primary in Metastatic Neuroendocrine Tumors. Surgery, 156, 1359-1365. https://doi.org/10.1016/j.surg.2014.08.008
|
[28]
|
Yang, Z., Klimstra, D.S., Hruban, R.H., et al. (2017) Immunohistochemical Characterization of the Origins of Metastatic Well-Differentiated Neuroendocrine Tumors to the Liver. The American Journal of Surgical Pathology, 41, 915-922. https://doi.org/10.1097/PAS.0000000000000876
|
[29]
|
Alexandraki, K., Angelousi, A., Boutzios, G., et al. (2017) Management of Neuroendocrine Tumors of Unknown Primary. Reviews in Endocrine & Metabolic Disorders, 18, 423-431. https://doi.org/10.1007/s11154-017-9437-9
|
[30]
|
Iwao, M., Nakamuta, M., Enjoji, M., et al. (2001) Pri-mary Hepatic Carcinoid Tumor: Case Report and Review of 53 Cases. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 7, 746-750.
|
[31]
|
Nishimori, H., Tsuji, K., Miyamoto, N., et al. (2005) Recurrence of Primary Hepatic Carcinoid Tumor in the Remnant Liver 13 yr after Resection. International Journal of Gastrointestinal Cancer, 35, 147-151.
https://doi.org/10.1385/IJGC:35:2:147
|
[32]
|
Knox, C.D., Anderson, C.D., Lamps, L.W., et al. (2003) Long-Term Survival after Resection for Primary Hepatic Carcinoid Tumor. Annals of Surgical Oncology, 10, 1171-1175. https://doi.org/10.1245/ASO.2003.04.533
|
[33]
|
Tamburrino, D., Spoletini, G., Partelli, S., et al. (2016) Surgical Management of Neuroendocrine Tumors. Best Practice & Research Clinical Endocrinology & Metabolism, 30, 93-102. https://doi.org/10.1016/j.beem.2015.10.003
|
[34]
|
Qu, C., Qu, L.L., Zhu, C.Z., et al. (2018) Treatment of Primary Hepatic Neuroendocrine Tumors with Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS): A Case Report and Literature Review. Medicine, 97, e12408. https://doi.org/10.1097/MD.0000000000012408
|
[35]
|
Sposito, C., Droz dit Busset, M., Citterio, D., et al. (2017) The Place of Liver Transplantation in the Treatment of Hepatic Metastases from Neuroendocrine Tumors: Pros and Cons. Reviews in Endocrine & Metabolic Disorders, 18, 473-483. https://doi.org/10.1007/s11154-017-9439-7
|
[36]
|
吕品, 孙世波, 陈晓宁. 原发性肝脏神经内分泌肿瘤的诊治进展[J]. 肝胆胰外科杂志, 2017, 29(6): 511-514.
|
[37]
|
Moris, D., Tsilimigras, D.I., Ntanasis-Stathopoulos, I., et al. (2017) Liver Transplantation in Patients with Liver Me
tastases from Neuroendocrine Tumors: A Systematic Review. Surgery, 162, 525-536.
https://doi.org/10.1016/j.surg.2017.05.006
|
[38]
|
Uri, I., Avniel-Polak, S., Gross, D.J., et al. (2017) Update in the Therapy of Advanced Neuroendocrine Tumors. Current Treatment Options in Oncology, 18, 72.
|
[39]
|
Niessen, C., Thumann, S., Beyer, L., et al. (2017) Percutaneous Irreversible Electroporation: Long-Term Survival
Analysis of 71 Patients with Inoperable Malignant Hepatic Tumors. Scientific Reports, 7, Article No. 43687.
https://doi.org/10.1038/srep43687
|
[40]
|
Do Minh, D., Chapiro, J., Gorodetski, B, et al. (2017) Intra-Arterial Therapy of Neuroendocrine Tumour Liver Metastases: Comparing Conventional TACE, Drug-Eluting Be Ads TACE and yttrium-90 Radioembolisation as Treatment Options Using a Propensity Score Analysis Model. European Radiology, 27, 4995-5005.
https://doi.org/10.1007/s00330-017-4856-2
|
[41]
|
Braat, A., Kappadath, S.C., Ahmadzadehfar, H., et al. (2019) Radioembolization with (90)Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity. Cardiovascular and Interventional Radiology, 42, 413-425. https://doi.org/10.1007/s00270-018-2148-0
|
[42]
|
Jia, Z. Wang, W. (2018) Yttrium-90 Radioembolization for Un-resectable Metastatic Neuroendocrine Liver Tumor: A Systematic Review. European Journal of Radiology, 100, 23-29. https://doi.org/10.1016/j.ejrad.2018.01.012
|
[43]
|
Kennedy, A., Bester, L., Salem, R, et al. (2015) Role of Hepatic IntRa-ARTERIAL Therapies in Metastatic Neuroendocrine Tumours (NET): Guidelines from the NET-LIVER-Metastases Consensus Conference. Hpb: The Official Journal of the International Hepato Pancreato Biliary Association, 17, 29-37. https://doi.org/10.1111/hpb.12326
|
[44]
|
Merola, E.F. and Delle, 2017,A..F. () An-tiproliferative Effect of Somatostatin Tumors: A Systematic Review and Meta-Analysis. Oncotarget, 8, 46624-46634. https://doi.org/10.18632/oncotarget.16686
|
[45]
|
Rinke, A., Muller, H.H., Schade-Brittinger, C., et al. (2009) Pla-cebo-Controlled, Double-blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group. Journal of Clinical Oncology, 27, 4656-4663.
https://doi.org/10.1200/JCO.2009.22.8510
|
[46]
|
Zhao, Z.M., Wang, J., Ugwuowo, U.C., et al. (2018) Primary Hepatic Neuroendocrine Carcinoma: Report of Two Cases and Literature Review. BMC Clinical Pathology, 18, 3.
|
[47]
|
Yao, J.C., Guthrie, K.A., Moran, C., et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide plus Interferon Alfa-2b versus Depot Octreotide plus Bevacizumab in Patients with Advanced Carcinoid Tumors: SWOG S0518. Journal of Clinical Oncology, 35, 1695-1703. https://doi.org/10.1200/JCO.2016.70.4072
|
[48]
|
Shah, M.H., Goldner, W.S., Halfdanarson, T.R., et al.( 2018) NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal of the National Compre-hensive Cancer Network, 16, 693-702.
https://doi.org/10.1038/srep43687
https://doi.org/10.6004/jnccn.2018.0056
|
[49]
|
Bodei, L., kwekkeboom, D.J., Kidd, M., et al. (2016) Radiolabeled Somatostatin Analogue Therapy of Gastroenteropancreatic CANCER. Seminars in Nuclear medicine, 46, 225-238. https://doi.org/10.1053/j.semnuclmed.2015.12.003
|
[50]
|
Strosberg, J., El-Haddad, G., Wolin, E., et al. (2017) Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. The New England Journal of Medicine, 376, 125-135. https://doi.org/10.1056/NEJMoa1607427
|
[51]
|
Carlsen, E.A., Fazio, N., Granberg, D, et al. (2019) Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic NEN G3: A Multicenter Cohort Study. Endocrine-Related Cancer, 26, 227-239. https://doi.org/10.1530/ERC-18-0424
|
[52]
|
Lamberti, G., Brighi, N., Maggio, I., et al. (2018) The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy? International Journal of Molecular Sciences, 19.
|
[53]
|
Chan, D.L., Segelov, E. and Singh, S. (2018) Everolimus in the Management of Metastatic Neuroendocrine Tumors. Therapeutic Advances in Gastroenterology, 10, 132-141.
|
[54]
|
Singh, S., Carnaghi, C., Buzzoni, R., et al. (2018) Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology, 106, 211-220. https://doi.org/10.1159/000477585
|
[55]
|
Grillo, F., Florio, T., Ferrau, F., et al. (2018) Emerging Multitarget Tyrosine Kinase Inhibitors in the Treatment of Neuroendocrine Neoplasms. Endocrine-Related Cancer, 25, R453-466. https://doi.org/10.1530/ERC-17-0531
|
[56]
|
Raymond, E., Dahan, L., Raoul, J.L., et al. (2011) Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. The New England Journal of Medicine, 364, 501-513. https://doi.org/10.1056/NEJMoa1003825
|
[57]
|
Chan, D.L. and Singh, S. (2018) Current Chemotherapy Use in Neuroendocrine Tumors. Endocrinology & Metabolism Clinics of North America, 47, 603-614. https://doi.org/10.1016/j.ecl.2018.04.006
|
[58]
|
Garcia-Carbonero, R., Rinke, A., Valle, J.W., et al. (2017) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy. Neuroendocrinology, 105, 281-294.
https://doi.org/10.1159/000473892
|
[59]
|
Faggiano, A., lo Calzo, F., Pizza, G., et al. (2017) The Safety of Available Treatments Options for Neuroendocrine Tumors. Expert Opinion on Drug Safety, 16, 1149-1161. https://doi.org/10.1080/14740338.2017.1354984
|